Publications by authors named "A Bosi"
Importance: COVID-19 infection has been associated with acute kidney injury. However, its possible association with long-term kidney function is not well understood.
Objective: To investigate whether kidney function decline accelerated after COVID-19 compared with after other respiratory tract infections.
Objective: Low estimated glomerular filtration rate (eGFR) increases the risk of arterial diseases, possibly including abdominal aortic aneurysm (AAA). This study explored the relationship between eGFR (2008 CKD-EPI equation), annual eGFR decline, and subsequent risk of developing AAA in a large, community based sample.
Methods: This was an observational study using complete healthcare records of Stockholm residents free from AAA who underwent routine creatinine testing during 2011 - 2021.
Article Synopsis
- Several types of severe asthma are linked to immune pathways, specifically type 2 inflammation, but asthma without this inflammation is harder to treat and responds poorly to standard therapies.
- Epithelial cells play a crucial role in asthma by releasing alarmin cytokines like IL-25, IL-33, and TSLP when triggered by allergens or infections, which increases inflammation and barrier permeability.
- The biologic drug tezepelumab (TZP) targets TSLP and has shown promise in clinical trials as a safe and effective treatment for severe asthma, with the review providing insights for clinicians on identifying the best candidates for this therapy.
Diagnostic boundaries between immune thrombocytopenia (ITP) and other thrombocytopenic states such as thrombocytopenic myelodysplastic syndromes, may be difficult to establish, and the detection of somatic mutations by next generation sequencing (NGS) may be of aid. Here we aimed at characterizing the prevalence and clinical significance of clonal hematopoiesis in ITP. In this multicentric retrospective observational study we enrolled 167 adult ITP patients, followed at 13 centers in Italy, UK, and USA.
View Article and Find Full Text PDFArticle Synopsis
- A study was conducted to determine if sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduce the risk of hyperkalemia and help maintain the use of renin-angiotensin system inhibitors (RASi) in people with type 2 diabetes, compared to dipeptidyl peptidase 4 inhibitors (DPP-4i).
- The research involved nearly 30,000 adults in Stockholm over several years, measuring incidents of hyperkalemia and RASi discontinuation in those starting either SGLT-2i or DPP-4i.
- Results showed that SGLT-2i users had significantly lower rates of hyperkalemia (both mild and